Stemline Announces Four SL-401 Presentations at Upcoming ASH Meeting
November 1, 2017
NEW YORK , Nov. 01, 2017 (GLOBE NEWSWIRE)
Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel therapeutics for difficult to treat cancers, announced today that SL-401, a novel targeted therapeutic directed to CD123, will be featured in four presentations at the 2017 American Society of Hematology (ASH) Annual Meeting and Exposition, to be held December 9-12, 2017 in Atlanta, GA. The full abstracts are now available on the ASH conference website.
